Microbiology
Hassan Tizfahm Tikmehdash; Alireza Dehnad; Nader Mosavari; Behroz Naghili Hokmabadi; Sanaz Mahmazi
Articles in Press, Accepted Manuscript, Available Online from 13 March 2024
Abstract
Glanders caused by Burkholderia mallei is one of the most dangerous zoonotic diseases in solipeds. Clinical diagnosis of this disease in its early stages in horses, is difficult. This study investigated serological and molecular identification of B. mallei in East Azerbaijan province. In the third and ...
Read More
Glanders caused by Burkholderia mallei is one of the most dangerous zoonotic diseases in solipeds. Clinical diagnosis of this disease in its early stages in horses, is difficult. This study investigated serological and molecular identification of B. mallei in East Azerbaijan province. In the third and fourth quarters of 2020, throughout 2021, and in the first and second quarters of 2022, the complement fixation test (CFT) was performed on 350 horses. The malleination was used to confirm the positive CFT cases. Blood samples were taken for culture and for preparing serums to perform the ELISA. Deep eye discharge, nostril, cutaneous ulcers, and lymph fluid swabs were cultured, and finally, PCR was carried out. Eleven (3.14%) horses were CFT-positive. Based on the malleination on these 11 horses, six (1.7%) were affected by glanders, five (1.42%) were not affected (false positive), and one horse (0.28%) was CFT-negative despite exhibiting clinical signs. It was positive by malleination, ELISA, and PCR. A total of seven positive cases of glanders were diagnosed. B. mallei could not be isolated, but the B. cepacia complex was isolated in one case. Except for three cases (14.28%), the results of the CFT, mallein, and ELISA tests were consistent (71.42%). The amount of confidence interval (CI) was 95%. It is suggested that ELISA be used as a complement to CFT in screening and, if positive results are observed in one of the tests, the entire herd be examined more accurately using the mallein and western blot confirmatory tests.
Microbiology
Somayeh Bahrami; Mohammad Mehdi Feizabadi; Nader Mosavari; Fattah Sotoodehnejad; Mohammad Eslampanah
Volume 14, Issue 12 , December 2023, , Pages 659-664
Abstract
The new strategy for vaccine development such as the fused protein multi-epitope capable of preventing the reactivation of latent tuberculosis infection (LTBi) can be an effective strategy for controlling tuberculosis (TB) worldwide. This study was conducted to evaluate the immunity of experimentally ...
Read More
The new strategy for vaccine development such as the fused protein multi-epitope capable of preventing the reactivation of latent tuberculosis infection (LTBi) can be an effective strategy for controlling tuberculosis (TB) worldwide. This study was conducted to evaluate the immunity of experimentally infected BALB/c mice with Mycobacterium tuberculosis after injection of DNA construct. Nineteen female BALB/c mice were divided into three groups and injected with 0.50 mL of M. tuberculosis. After 3 weeks, lung and spleen samples from the infected mice were examined. The protective effects of light chain 3-fused protein multi-epitope against TB were evaluated for post-exposure and therapeutic exposure. The lungs and spleens of the mice were aseptically removed after death for histopathology analysis. The bacterial colonies were counted, and the cells were stained after 3 weeks of incubation. No significant differences were observed between the post-exposure and therapeutic exposure groups. The pathological changes in the lung tissue of mice in these groups included an increase in the thickness of interalveolar septa, hyperemia, and intraparenchymal pulmonary hemorrhage centers (positive control), scattered hyperemic areas (negative control), and hyperemia in the interstitial tissue, scattered hyperemic areas in the lung parenchyma and lymphocytic infiltration centers (experimental group). Flow cytometry of the post-exposure and therapeutic exposure models showed insignificant changes in all three groups. It seems necessary to develop a post-exposure and therapeutic exposure vaccine strategy that focuses on LTBi to prevent the progression of the active disease. In this regard, multi-epitope vaccines should be designed to induce both cellular and humoral immunity.